A prospective comparative study of intravesical Bacillus Calmette-Guerin (BCG) therapy with the Tokyo or Connaught strains for non-muscle invasive bladder cancer
Phase of Trial: Phase IV
Latest Information Update: 16 May 2016
Price : $35 *
At a glance
- Drugs BCG (Primary) ; BCG (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 07 May 2013 Results presented at the 108th Annual Meeting of the American Urological Association.
- 19 Mar 2013 Results presented at the 28th Congress of the European Association of Urology.
- 19 Dec 2012 New trial record